HARBIN, China, April 24 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) (OTC Bulletin Board: CSKI), a leading fully integrated pharmaceutical company for external use over-the-counter drugs in the People’s Republic of China (“PRC”), today announced its successful participation in the 103rd China Import and Export Fair in Guangzhou, China from April 15th to April 30th 2008.
With more than a fifty year history, the China Import and Export Fair is one of the most well attended trade shows in China, and it boasts the widest array of products from around the globe. This year, there were more than 300,000 people attended the trade show, representing industries as diverse as clothing, chemicals, computers, auto, foods, electronics, energy, appliances, drinks, pharmaceuticals and machinery. Among the 300,000 attendees, about 200,000 came from 213 countries outside of China. The China Import and Export Fair is considered by many businesses to be the most effective exhibition in China, as it generates a high volume of transactions.
At the trade show, China Sky One Medical presented its patch products and diagnostic kits. The Slim Patch Body-Beauty Plaster product in particular attracted attention due to its revolutionary technique in weight reduction. The Company’s booth attracted more than 1,200 visitors and over 100 distribution companies, including several major distributors that expressed strong interest in licensing and distributing the Company’s products.
“We are excited about the overwhelming response that our products received at the China Import and Export Fair. It demonstrates the strong brand name recognition for our products as well as large customer demand. We intend to continue with our strategy of developing high quality products and expanding our sales and marketing efforts globally,” said Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical, Inc.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (‘‘TDR’’) and Harbin First Bio-Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
China Sky One Medical, Inc.
Ms. Xiaoyan Han, CFO
Tel: +86-1335-999-3681
Email: tdrhan@163.com
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com